Inotuzumab Ozogamicin
Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)
First Affiliated Hospital of Zhejiang Universityantibody_drug_conjugatePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
24 Active assets in the Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Blinatumomab Amgen | Phase 3 | BBB |
Fludarabine National Cancer Institute (NCI) | Phase 2/3 | BB |
Cyclophosphamide Princess Maxima Center for Pediatric Oncology | Phase 2/3 | BB |
Cytosin-Arabinosid Princess Maxima Center for Pediatric Oncology | Phase 2 | B |
METHOTREXATE First Affiliated Hospital of Zhejiang University | Phase 2 | B |
View all 28 →
Same molecule, other indications
Inotuzumab Ozogamicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →